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ABSTRACT 
 
Background: Transient elastography measures liver stiffness, which correlates 
with the hepatic fibrosis stage and has excellent accuracy for the diagnosis of cirrhosis 
in patients with chronic hepatitis C. 
Aim: To prospectively assess the kinetics of liver stiffness in treated patients with 
chronic hepatitis C and compare them with the viral kinetics on treatment and with the 
final outcome of therapy. 
Methods: 91 patients with chronic hepatitis C with significant fibrosis (>7.0 kPa) 
at baseline were included. They received therapy with pegylated interferon-α and 
ribavirin. The kinetics of liver stiffness were characterized during therapy and thereafter 
by means of Fibroscan®, and compared with the virological responses at weeks 4, 12, 
24, end of treatment and 12 and 24 weeks after.  
Results: A significant liver stiffness decrease was observed during therapy, 
which continued after treatment only in patients who achieved a sustained virological 
response. In this group, the median intra-patient decreas  relative to baseline at the end 
of follow-up was -3.4 kPa, vs -1.8 kPa in the patients who did not achieve an SVR. 
Similar dynamics were observed in cirrhotic and non-cirrhotic patients. In multivariate 
analysis, only the SVR was associated with long-term improvement of liver stiffness 
(odds ratio: 3.10; 95% confidence interval: 1.20-8.02, p=0.019). 
Conclusions:In patients with advanced fibrosis at the start of therapy, liver 
stiffness is significantly reduced during treatment, but improvement continues off 
treatment only in patients who achieve a sustained virological response. Liver stiffness 
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assessment earlier than 6 months after the end of therapy does not appear to be 
clinically meaningful. 
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Chronic infection with hepatitis C virus (HCV) is the leading cause of chronic liver 
disease in Europe and the United States. Chronic hepatitis C is responsible for 
substantial morbidity and mortality related to liver cirrhosis and its complications, 
including hepatocellular carcinoma.1 Nowadays, HCV is becoming the first cause of 
primary liver cancer and is the main indication for liver transplantation in industrialized 
countries.1 The current standard treatment of chronic hepatitis C is a combination of 
pegylated interferon (IFN)-α and ribavirin.2 With this treatment, a sustained virological 
response, defined as an undetectable HCV RNA 24 weeks after the end of therapy, is 
achieved in approximately 40%-50% of patients infected with HCV genotype 1 and in 
80% of those infected with genotypes 2 and 3.3-5 
The hepatic fibrosis stage is the principal predictor of liver disease progression 
and drives treatment indications.2 Liver biopsy examination has traditionally been 
considered the reference method for staging liver fibrosis. It is recommended in recent 
Clinical Practice Guidelines for treatment decision in patients with chronic hepatitis C.2 
However, the accuracy of liver biopsy has been questioned, as sampling errors and 
intra- and inter-observer variability may lead to under- or over-staging.6-9 In addition, 
liver biopsy is an invasive procedure with rare, but potentially life-threatening, 
complications.10-13 These limitations have stimulated the search for noninvasive 
approaches for liver disease severity assessment, including serological markers and 
methods based on ultrasonography, such as transient elastography.14-17 
Transient elastography by means of the Fibroscan® (Echosens, Paris, France) 
measures liver stiffness. It can be performed at the bedside with immediate results and 
Page 4 of 27Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 5 
has been reported to be rapid, user-friendly and reproducible.18 Liver stiffness has been 
shown to correlate with the hepatic fibrosis stage and to have excellent accuracy for the 
diagnosis of cirrhosis in patients with chronic hepatitis C.19-22 Thus far, transient 
elastography has been used and validated essentially in cross-sectional studies, 
whereas the kinetics of liver stiffness in patients with chronic hepatitis C receiving 
antiviral therapy have not been characterized in prospective longitudinal studies. 
The goal of this study was to prospectively assess the kinetics of liver stiffness in 
patients with chronic hepatitis C treated with pegylated IFN-α and ribavirin and to 
compare them with the HCV RNA level kinetics on treatment and with the final outcome 
of therapy. 
 
PATIENTS AND METHODS 
 
Patients 
This multicentre, prospective study was conducted in 5 French hospitals between 
January 2005 and March 2007. One hundred and five patients with chronic hepatitis C, 
i.e. patients with chronically elevated serum alanineaminotransferase (ALT) levels and 
detectable serum anti-HCV antibodies and HCV RNA, were included. All of them were 
treatment-naïve and the main inclusion criterion was significant fibrosis, defined as liver 
stiffness >7.0 kilopascals (kPa) with the Fibroscan® at baseline.20 The exclusion criteria 
were: a coinfection with hepatitis B virus or human immunodeficiency virus, a daily 
alcohol intake >30 g, decompensated liver disease or hepatocellular carcinoma, liver 
transplantation, and a failed or unreliable liver stiffness measurement.23 
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The study protocol conformed to the ethical guidelines of the 1975 Helsinski 
declaration and the French regulations on clinical trials, and was approved by the 
Institutional Review Board (Comité de Protection des Personnesd’Ile-de-France IX). The 
patients were enrolled after giving their written informed consent.  
 
Antiviral therapy 
The 105 patients received standard-of-care therapy with either pegylated IFN-α2a 
(Pegasys®, Hoffman-La Roche, Basel, Switzerland), 180 µg once weekly, or pegylated 
IFN-α2b (PegIntron®, Schering-Plough, Kenilworth, New Jersey), 1.5 µg/kg once weekly, 
and ribavirin, 1.0-1.2 g/day according to body weight below or above 75 kg, respectively, 
in patients infected with genotypes 1 and 4, or 0.8 g/day in patients infected with HCV 
genotypes 2 and 3. Treatment duration was 48 weeks in patients infected with HCV 
genotypes 1 and 4 (with a stopping rule at week 12 if the HCV RNA decline was less 
than 2 Log10 international units (IU)/mL), and 24 weeks in patients infected with HCV 
genotypes 2 and 3.  
 
Monitoring schedule and definition of virological responses 
ALT levels, HCV RNA levels and liver stiffness were evaluated at baseline, at 
weeks 4, 12, and 24 of therapy in all patients, at week 48 of therapy in patients infected 
with HCV genotypes 1 and 4, and 12 and 24 weeks after treatment withdrawal in all 
patients. On treatment, virological responses were defined as follows: rapid virological 
response (RVR): undetectable HCV RNA at week 4; early virological response (EVR): 
undetectable HCV RNA at week 12; end-of-treatment response (EOTR): undetectable 
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HCV RNA at the end of treatment, i.e. week 24 or 48 in patients infected with HCV 
genotypes 2-3 and 1-4, respectively. The sustained virological response (SVR) was 
defined as an undetectable HCV RNA 24 weeks after the end of therapy.  
 
HCV RNA level measurement 
HCV RNA levels were measured centrally by means of the m2000SP/m2000RT 
real-time PCR platform (Abbott Molecular, Des Plaines, Illinois), according to the 
manufacturer’s instructi ns. The assay has been shown to accurately quantify HCV RNA 
levels regardless of the HCV genotype.24 Its lower limit of detection is 12 IU/mL. 
Undetectable HCV RNA at the different time points was thus defined as an HCV RNA 
level <12 IU/mL. 
 
Liver stiffness measurement 
Liver stiffness measurements were performed with the FibroScan® device, as 
previously described.14 Ten validated measurements were performed for each patient. 
The success rate was calculated as the number of validated measurements divided by 
the total number of measurements. The results were expressed in kilopascals. The 
median value was considered representative of the elastic modulus of the liver. Only 
procedures with at least ten successful acquisitions, a success rate of at least 60% and 
an interquartile range (IQR) of less than 30% of the median value were considered 
reliable.18 Patients with baseline liver stiffness values above 13 kPa were considered to 
have cirrhosis.21Long-term improvement of liver stiffness was defined as a decrease of 
at least 30% of median values 6 months after treatment withdrawal relative to baseline, 
as the manufacturer allows fluctuations of 30% of the IQR relative to the median value.18 
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Statistical analysis 
Results are expressed as the mean ± 1 standard deviation for normally distributed 
variables (age, body mass index [BMI]) and as the median with IQR (1st and 3rd 
quartiles) for variables with asymmetric distribution (ALT, HCV RNA level and liver 
stiffness). Intra-group comparisons were made using Wilcoxon’s test for paired data. 
Categorical data were expressed as numbers and percentages, and compared by 
means of the Chi-square test or Fisher’s exact test where appropriate. The relationship 
between quantitative data was tested by linear regression analysis. 
The factors associated with long-term improvement of liver stiffness were tested 
by univariate analysis (chi-square test, Mann and Whitney test). Variables with a p value 
≤0.10 were then tested in a logistic regression model by a forward step-by-step 
procedure. Odds ratios (OR) and their 95 % confidence intervals (CI) were inferred from 
the model. A p value ≤0.05 was considered significant.  
 
RESULTS 
 
Patient characteristics and disposition 
Among the 105 patients prospectively included in the study, 8 were lost to follow-
up and an additional 6 patients did not complete follow-up (more than 2 missing time 
points) and were excluded from the analysis. These 14 patients did not differ from the 
other treated patients for age, gender, BMI, frequency of cirrhosis, HCV genotype, and 
baseline HCV RNA level, ALT level, and liver stiffness.  
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Overall, 91 treated patients were analyzed. There were 63 men and 28 women, 
and their mean age was 52.4±11.6 years. Their characteristics are shown in Table 1. 
Among the 91 patients, 2 were treated for 12 weeks only (one patient who did not 
achieve a 2-Log10 HCV RNA drop at week 12 and one who achieved an RVR and 
stopped therapy at week 12); 47 patients infected with genotype 2 or 3 were treated for 
24 weeks; and 42 patients infected with genotype 1, 4 or 6 were treated for 48 weeks. 
An RVR and an EVR were observed in 31 patients (34.1%) and 25 patients (27.5%), 
respectively. An SVR was observed in 59 patients (64.8%).  
 
Median liver stiffness changes according to the virological response 
Table 2 shows the median intra-patient changes in liver stiffness relative to 
baseline in the patients who achieved or did not achieve an SVR. No significant 
relationship was found between liver stiffness changes and the RVR, EVR or EOTR 
(data not shown). A significant liver stiffness decrease was observed during pegylated 
IFN-α and ribavirin administration in the patients who achieved an SVR, as well as in 
non-sustained virological responders (median changes at the end of treatment relative to 
baseline: -2.0 kPa, p<0.001, and -2.9 kPa, p=0.02, respectively) (Figures 1A and 1B, 
Table 2). After treatment, liver stiffness continued to significantly decrease relative to 
end-of-treatment in the patients who achieved an SVR (median change: -0.7 kPa, 
p=0.008), resulting in a median intra-patient decrease relative to baseline at the end of 
follow-up of -3.4 kPa (p<0.001) (Figure 1B and Table 2). In contrast, in patients who did 
not achieve an SVR, liver stiffness increased after the end of treatment (median change: 
+0.8 kPa, p=0.59), resulting in a median intra-patient decrease of liver stiffness relative 
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to baseline of -1.8 kPa (p=0.03) (Figure 1A and Table 2). However, as shown in Figure 
2, in spite of the global trends, there were important differences in liver stiffness kinetics 
between individual patients.  
 
Liver stiffness changes according to the virological response in cirrhotic 
patients 
When cirrhotic and non-cirrhotic patients were considered separately, liver 
stiffness values were always significantly higher in the former than in the latter, but the 
same dynamics as in the global analysis were seen. They are presented in Table 3. 
 
Liver stiffness changes according to ALT changes 
No relationship was observed between liver stiffness and ALT changes during 
and after therapy, regardless of the virological outcome of treatment (data not shown). 
 
Variables associated with long-term improvement of liver stiffness 
Long-term improvement of liver stiffness was defined as a decrease of median 
liver stiffness between baseline and end of follow-up of 30% or more. Long-term liver 
stiffness improvement was observed in 38 patients. Table 4 shows the factors that 
predicted liver stiffness improvement in univariate analysis. In multivariate analysis, only 
the SVR was associated with long-term improvement of liver stiffness, with an odds ratio 
of 3.10 (95% confidence interval: 1.20-8.02, p=0.019). 
 
DISCUSSION 
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Successful therapy with IFN-α or pegylated IFN-α with or without ribavirinhas 
been shown to be associated with significant histological improvements in studies in 
which patients underwent paired liver biopsies.25-29 However, follow-up liver biopsy is not 
part of the routine management of patients with chronic HCV infection receiving antiviral 
therapy.2 Therefore, non-invasive methods appear to be better suited to the monitoring 
of liver disease outcomes during and after therapy. Given its simplicity, high acceptability 
by patients and intrinsic performance.19-21, 30, 31 transient elastography is an appropriate 
tool for the longitudinal f llow-up of fibrosis changes in treated HCV-infected patients, as 
shown in the present study. 
In this multicentre study conducted in expert centres for transient elastography 
and HCV virology, we characterized the dynamics of liver stiffness in patients with 
significant fibrosis at baseline (defined as liver stiffness >7.0 kPa with the Fibroscan®) 
treated with pegylated IFN-α and ribavirin. Liver stiffness and HCV RNA kinetics were 
assessed at multiple time points during and after therapy and compared. We observed 
that liver stiffness significantly decreased on treatment both in patients who did and did 
not achieve an SVR. However, liver stiffness continued to significantly decrease after the 
end of treatment only in patients who achieved an SVR. On treatment, no relationship 
was found with RVR, EVR or EOTR. Overall, both patients who achieved and those who 
did not achieve an SVR experienced a significant decrease of liver stiffness at the end of 
follow-up relative to baseline, but this decrease was greater in the sustained virological 
responders (p=0.11). These results are in keeping with a previous observation in 
patients who were assessed at the end of treatment and thereafter.32 The use of mean 
values for a non-normally distributed variable such as liver stiffness was however 
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questionable in this study, as median values better reflect the distribution and extreme 
values. In another study,33 a significant liver stiffness decrease was reported at the end 
of follow-up in patients treated with pegylated IFN-α and ribavirin, regardless of the final 
virological outcome of therapy (SVR or non-SVR). No on-treatment monitoring was 
available, and liver stiffness at baseline significantly differed among the study groups. 
However, the latter was also the case in our study, with median values of 12 kPa 
(interquartile range, IQR: 9.6-24.7) in non-SVR vs 10 kPa (8.2-14.1) in SVR patients. 
Overall, our prospectively generated data suggest that the cure of HCV infection 
is associated with a significant reduction of liver stiffness, as measured by transient 
elastography. This result may appear surprising as transient elastography is claimed to 
assess essentially the fibrotic component of liver lesions, while treatment has been 
mostly associated with reduction of the inflammatory reaction in the liver. Two non-
mutually exclusive hypotheses can be raised to explain this result: (i) liver stiffness is 
also influenced by the local inflammatory reaction; (ii) fibrosis significantly regresses on 
treatment and thereafter in patients who achieve an SVR. The first hypothesis may 
appear unlikely as no relationship was observed between liver stiffness changes and 
ALT kinetics; however, ALT elevations do not always accurately reflect liver 
inflammation. On the other hand, SVR was the sole predictor of long-term liver stiffness 
improvement; nevertheless, SVR is also associated with an improvement of liver 
inflammation. Therefore, this hypothesis cannot be definitively ruled out. Indeed, others 
have reported an overestimation of liver stiffness in patients with liver inflammation 
reflected by high ALT levels.15, 34-37 In addition, a significant decrease of liver stiffness 
was observed during therapy, followed by an increase after treatment withdrawal, in the 
Page 12 of 27Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 13 
patients from this study who did not clear HCV infection. Histological data might have 
helped resolve this question. However, liver biopsy can no longer be performed during 
or after antiviral treatment for ethical reasons. Therefore, this question will remain 
unanswered. 
Our hypothesis concerning liver stiffness changes in patients who achieved an 
SVR witnessing fibrosis regression is in keeping with the reported improvement of 
histological fibrosis in a similar population who underwent paired liver biopsies.25-29 It is 
also in keeping with the lower incidence of clinical outcomes, including liver failure, 
variceal bleeding or hepatocellular carcinoma, in patients with cirrhosis who achieved an 
SVR.38-41 However, although patients with cirrhosis who achieved an SVR experienced a 
significant improvement of their liver stiffness 6 months after the end of treatment in our 
study, their median liver stiffness values remained significantly higher than in patients 
without cirrhosis who achieved an SVR. In this context, the fact that the risk of 
developing HCC remains substantial in cirrhotic patients who achieved an SVR.26, 38, 40 is 
not surprising. 
In conclusion, the results of this prospective, multicentre study show that transient 
elastography can be used to monitor liver stiffness changes during and after antiviral 
therapy in patients with chronic hepatitis C. On average, in patients with advanced 
fibrosis at the start of therapy (>7.0 kPa), liver stiffness is significantly reduced during 
pegylated IFN-α and ribavirin administration. The significant reduction of liver stiffness 
continues off treatment only in patients who achieve an SVR. This probably denotes 
fibrosis regression, although it cannot be ruled out that improvements in the 
inflammatory reaction in these patients may also influence liver stiffness changes. These 
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findings suggest that assessing liver stiffness by means of transient elastography at 
baseline and 6 months after treatment in patients who achieve an SVR is useful to 
assess the global response to antiviral therapy, establish a prognosis and serve as a 
basis for subsequent follow-up in patients with advanced fibrosis, especially those with 
cirrhosis. In the latter, post-treatment liver stiffness assessments should not be 
substituted to the recommended periodic surveillance of hepatocellular carcinoma 
occurrence based on ultrasound examination and  α-fetoprotein level measurement.42 
Our data also suggest that liver stiffness assessment earlier than 6 months after the end 
of therapy is not clinically meaningful. 
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FIGURE LEGENDS 
 
Figure 1. Median (IQR) intra-patient liver stiffness changes relative to baseline at 
different time points on treatment and after the end of therapy. (A) Patients who did not 
achieve an SVR. (B) Patients who achieved an SVR. 
 
Figure 2. Individual liver stiffness changes during and after treatment in patients who did 
not achieve an SVR and in patients who achieved an SVR. EOT: end of treatment; EOF: 
end of follow-up. 
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Table 1.Baseline characteristics of the 91 patients. 
 
  
Treated (N = 91) 
Male gender [n (%)] 63 (69.2) 
Age (yrs) [mean±SD] 52.4±11.6 
BMI (kg/m2) [mean±SD] 24.9±3.5 
ALT (IU/mL) [median (IQR)] 101 (63-153) 
HCV genotype [n (%)]  
   1-4-6 49 (54) 
   2-3 42 (46) 
HCV RNA level (Log10 IU/mL) [median (IQR)] 5.8 (5.2-6.2) 
Liver stiffness (kPa) [median (IQR)] 11.1 (8.4-16.3) 
Cirrhosis, i.e. liver stiffness ≥13.1 kPa [n (%)] 33 (36.3) 
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Table 2. Median (IQR) intra-patient liver stiffness changes relative to baseline on treatment and thereafter in patients who 
did and did not achieve an SVR. Treatment duration was 24 weeks in patients infected with HCV genotype 2 or 3, 48 
weeks in patients infected with HCV genotype 1, 4 or 6. P values are for intra-patient liver stiffness changes relative to 
baseline. 
 
SVR (N = 59) No SVR (N = 32) 
 
Time point Liver stiffness 
change p 
Liver stiffness 
change p 
Week 4 -1.0 (-3.4 - +0.3) 0.001 -1.3 (-5.1 - +0.4) 0.01 
Week 12 -2.2 (-4.0 - +0.2) <0.001 -1.1 (-3.8 - +0.2) 0.05 On treatment 
End of treatment -2.0 (-3.6 - +0.5) <0.001 -2.9 (-5.0 - -0.5) 0.02 
Follow-up week 12 -2.4 (-4.2 - +1.0) <0.001 -1.4 (-3.6 - +1.1) 0.08 
Post-treatment 
Follow-up week 24 -3.4 (-4.7 - -1.1) <0.001 -1.8 (-4.3 - +0.6) 0.03 
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Table 3. Median (IQR) intra-patient liver stiffness changes relative to baseline in patients with or without cirrhosis who did 
or did not achieve an SVR. Treatment duration was 24 weeks in patients infected with HCV genotype 2 or 3, 48 weeks in 
patients infected with HCV genotype 1, 4 or 6. P values are for intra-patient liver stiffness changes relative to baseline. 
 
Cirrhosis No cirrhosis 
 Time point 
SVR (n=19) p No SVR (n=14) p SVR (n=40) p 
No SVR 
(n=18) p 
Week 4 -4.1 (-8.6 - 0) 0.019 -4.7 (-16.9 - -0.5) 0.01 -0.7 (-2.1 - +0.4) 0.024 -1.0 (-2.3- +1.4) 0.41 
Week 12 -4.0 (-5.9 - +0.7) 0.025 -1.7 (-12.0 - +0.1) 0.035 -1.9 (-3.0 - -0.8) 0.001 -0.6 (-2.6- +1.9) 0.51 On treatment 
End of 
treatmenta -4.0 (-7.6 - +1.3) 0.059 -4.1 (-10.0 - -0.2) 0.07 -1.6 (-3.0 - +0.5) 0.001 -2.6 (-4.5- -0.8) 0.13 
Follow-up 
week 12 -3.3 (-13.4 - +2.5) 0.20 -2.3 (-9.7 - +1.6) 0.25 -2.3 (-3.8 - -0.8) <0.001 -0.8 (-2.3- +1.2) 0.32 
Post-treatment 
Follow-up 
week 24 -6.4 (-8.5 - -1.6) 0.001 -2.5 (-9.8 - +1.4) 0.14 -2.7 (-3.9 - -0.7) <0.001 -1.2 (-3.2- +0.7) 0.11 
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Table 4.Univariate analysis of variables associated with long-term liver stiffness improvement, defined as a liver stiffness 
decrease ≥30% relative to baseline 24 weeks after the end of therapy.  
 
 
Liver stiffness change 
<30% (N = 53) 
Liver stiffness change 
≥30% (N = 38) p 
Age (years) 54.2±12.3 49.2±10.2 0.17 
Male gender [n(%)] 39 (73.6) 24 (63.2) 0.29 
Baseline BMI (kg/m2) 25.2±3.7 24.5±3.3 0.19 
HCV genotype [n (%)]    
     Genotype 1-4-6 32 (65.3) 17 (34.7) 0.14 
     Genotype 2-3 21 (50.0) 21 (50.0)  
Baseline ALT level (IU/L) [median (IQR)] 110 (70-162) 91 (60-136) 0.34 
Baseline liver stiffness (kPa) [median (IQR)] 10.6 (7.8-16.3) 11.4 (9.1-15.8) 0.28 
Baseline HCV RNA level (Log10 IU/mL) [median (IQR)] 5.9 (5.3-6.3) 5.8 (5.2-6.3) 0.69 
Cirrhosis, i.e. liver stiffness >13 kPa [n (%)] 19 (35.8) 14 (36.8) 0.92 
Treatment duration    
     ≤24 weeks 24 (52.2) 22 (47.8) 0.24 
>24 weeks 29 (64.4) 16 (35.6)  
HCV RNA level 24 weeks after treatment (Log10 IU/mL) [median (IQR)] 0.85 (0.78-5.89) 0.78 (0.78-0.85) 0.027 
Virological response [n (%)]    
     No SVR 24 (75.0) 8 (25.0) 0.017 
     SVR 29 (49.2) 30 (50.8)  
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